NSC 675967
Alternative Names: APPALatest Information Update: 14 Sep 1998
Price :
$50 *
At a glance
- Originator Nonindustrial source
- Class Antineoplastics
- Mechanism of Action Protein tyrosine kinase inhibitors; Type II DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 14 Sep 1998 Profile reviewed
- 14 Sep 1998 No-Development-Reported for Cancer in United Kingdom (Unknown route)
- 21 Oct 1996 Preclinical development for Cancer in United Kingdom (Unknown route)